Meanwhile, some drug makers have been buying up the rights to once-cheap medicines and hiking prices by 1,000 per cent or more. #StopRxGreed —@AARPTXThe pharmaceutical executives expressed a general desire to lower costs for patients, but made no firm commitments. The CEOs said drug development is a risky and costly undertaking and that prices reflect investment in research and development. Richard Gonzalez, CEO of AbbVie Inc., was one of several pharmaceutical executives to appear before a U.S. Senate finance committee hearing on drug prices. The pharmaceutical industry is one of the most powerful lobbies in Washington.

Source: CBC News February 26, 2019 18:34 UTC